Dr. Irwin D. Bernstein

powered by
COS Expertise®
Fred Hutchinson Cancer Research Center
Clinical Research Division
Pediatric Oncology
MemberAppointed: 1981
University of Washington
School of Medicine
Pediatrics
ProfessorAppointed: 1981
Professional Headshot of Irwin D. Bernstein

Mailing Address

Fred Hutchinson Cancer Research Center
1100 Fairview Avenue N.
P.O. Box 19024
D2-373
Seattle, Washington 98109-1024
United States

Contact Information

Phone: (206) 667-4886
Fax: (206) 667-6084
ibernste@fhcrc.org

Qualifications

M.D., New York University, 1967.

Expertise and Research Interests

Normal and malignant hematopoietic development; targeted therapy of hematopoietic malignancies.

Our laboratory has been involved in studies of the maturation-linked expression of surface antigens by normal and malignant hematopoietic studies which have led to the development of methods for the isolation of human hematopoietic stem cells and for the use of these cells for in vivo transplantation. Current studies of normal hematopoiesis are aimed at determining methods to direct primitive hematopoietic precursors to commit to a particular maturational pathway or to self-renew. The studies focus on the role of two receptors thought to play a role in the regulation of cell fate decisions during hematopoietic differentiation: the human homologue of the Drosophila developmental gene, Notch, and retinoic acid receptors. Recent studies have demonstrated that constitutive Notch1 signaling can enhance self-renewal and immortolization cytokine-dependent pluripotent hematopoietic stem cells. We have further demonstrated that Notch signaling induced by interaction of hematopoietic precursor cells with exogenous Notch ligand enhances the formation of primitive multipotential precursors and are presently evaluating whether the formation of hematopoietic stem cells is also enhanced. Our goal is to determine conditions that lead to amplification of hematopoietic stem cell populations for therapeutic purposes.

Our studies of the clonal origin of AML have suggested that in some patients, the leukemic cells develop from a clone of mature CD33+ progenitors, or that the leukemia involves only occasional less mature CD33- precursor cells that expand in an uncontrolled manner after maturation to a CD33+ CFC. For these patients, we have hypothesized that ablation of CD33+precursors would restore normal hematopoiesis in patients with AML. On this basis, in collaboration with Wyeth-Ayerst, we have developed a conjugate for the selective ablation of CD33+ cells and demonstrated its ability to induce remissions in at least some patients with AML, supporting the notion of the predominantly or completely normal origin of the CD33- precursors. This conjugate has been approved by the FDA and our current studies are evaluating the role of multi-drug resistance genes in preventing effects of the conjugate and methods for reversing this resistance.

Our studies have also explored the use of hematopoietic differentiation antigens as targets for the selective delivery of therapy to tumors. In collaboration with Drs. Oliver Press, Dana Matthews, Fred Appelbaum, and Janet Eary, we have successfully used radiolabeled antibodies in conjunction with marrow transplantation in the treatment of leukemia and lymphoma. Nearly all treated lymphoma patients achieved a complete response, some of which are enduring now for more than three years. In studies of acute leukemia, we have used radiolabeled antibody to augment total body radiation prior to marrow transplantation. These studies are continuing to document the therapeutic efficacy of radiolabeled antibody and to develop improved methods for the delivery of radioisotopes to tumor.

Other Expertise

PROGRAM IN PEDIATRIC ONCOLOGY

The overall aim of the Pediatric Oncology Program is to improve the outcome for children with malignancy. Since its inception, research in this program has focused on developmental aspects of hematopoiesis with the specific goal of developing novel therapeutic modalities. In these efforts we have identified maturation linked cell surface antigens and have utilized this information for developing methods for targeted therapy of hematologic malignancies and for isolating and characterizing normal and malignant human hematopoietic stem cells. These studies have led to the development of stem cell transplantation using isolated CD34+ cells, successful targeted radiotherapy of leukemia and lymphoma, and the development of anovel approach for treating AML using an antibody-drug conjugate. Current studies are also evaluating novel approaches for expanding and genetically altering hematopoietic stem cells for therapeutic purpose. A new program is directed towards studying the developmental aspects of neuropoiesis with a focus on identifying therapeutic targets in tumors of the developing brain.

Keywords

COS Keywords:

Cancer or Carcinogenesis, Genetics, Medical Genetics, Oncology, Pediatrics.

Additional Terms:

Cancer, Genetics, Specific Cancers.

Memberships

American Cancer Society

Publications

  • Aoyama K, Delaney C, Varnum-Finney B, Kohn AD, Moon RT, Bernstein ID (2007 Jul 19; [Epub ahead of print]) The Interaction of The Wnt and Notch Pathways Modulates Nk vs. T Cell Differentiation., Stem Cells
  • Dallas MH, Varnum-Finney BJ, Martin PJ, Bernstein ID (2007) Enhanced T Cell Reconstitution by Hematopoietic Progenitors Expanded Ex-Vivo Using the Notch Ligand Delta1., Blood, 109 (8), 3579-87
  • Walter RB, Gooley TA, van der Velden VH, Loken MR, van Dongen JJ, Flowers DA, Bernstein ID, Appelbaum FR (2007) CD33 expression and P-glycoprotein-mediated drug efflux inversely correlate and predict clinical outcome in patients with acute myeloid leukemia treated with gemtuzumab ozogamicin monotherapy., Blood, 109 (10), 4168-70
  • Pollard JA, Alonzo TA, Gerbing RB, Woods WG, Lange BJ, Sweetser DA, Radich JP, Bernstein ID, Meshinchi S (2006) FLT3 internal tandem duplication in CD34+/CD33- precursors predicts poor outcome in acute myeloid leukemia., Blood, 108 (8), 2764-9
  • Dallas MH, Varnum-Finney B, Delaney C, Kato K, Bernstein ID (2005) Influence of CD33 expressing levels and ITIM-dependent internalization on gemtuzumab ozogamicin-induced cytotoxicity., Blood, 201 (9), 1361-6
  • Arceci RJ, Sande J, Lange B, Shannon K, Franklin J, Hutchinson R, Vik TA, Flowers D, Aplenc R, Berger MS, Sherman ML, Smith FO, Bernstein ID, Sievers EL (2005) Safety and Efficacy of Gemtuzumab Ozogamicin (Mylotarg®) in Pediatric Patients With Advanced CD33+-Positive Acute Myeloid Leukemia., Blood, 106 (4), 1183-88
  • Delaney C, Varnum-Finney B, Aoyama K, Brashem-Stein C, Bernstein ID (2005) Dose-dependent effects of the Notch ligand Delta1 on ex vivo differentiation and in vivo marrow repopulating ability of cord blood cells., Blood, 106 (8), 2693-9
  • Delaney C, Bernstein ID (2004) Establishment of a pluripotent preleukaemic stem cell line by expression of the AML1-ETO fusion protein in Notch1-immortalized HSCN1cl10 cells., Br J Haematol, 125, 353-357
  • Walter RB, Raden BW, Cronk MR, Bernstein ID, Appelbaum FR, Banker DE (2004) The peripheral benzodiazepine receptor ligand, PK11195, overcomes different resistance mechanisms to sensitize AML cells to gemtuzumab ozogamicin., Blood, 103 (11), 4276-4284
  • Hallahan AR, Pritchard JI, Hansen S, Benson M, Stoeck J, Hatton B, Russell TL, Bernstein ID, Beachy PA, Olson JM (2004) The SmoA1 mouse model reveals that notch signaling is critical for the growth and survival of Sonic Hedgehog induced medulloblastoma., Cancer Research, 64 (21), 7794-800
  • Walter RB, Raden BW, Thompson J, Flowers DA, Kiem H-P, Bernstein ID, Linenberger ML (2004) Breast cancer resistance protein (BCRP/ABCG2) does not confer resistance to gemtuzumab ozogamicin and calicheamicin-g1 in acute myeloid leukemia cells., Leukemia, 18 (11), 1914-7
  • Varnum-Finney B, Brashem-Stein C, Bernstein ID (2003) Combined effects of Notch signaling and cytokines induce a multiple log increase in precursors with lymphoid and myeloid reconstituting ability., Blood, 101, 1784-1789
  • Ohishi K, Katayama N, Shiku H, Varnum-Finney B, Bernstein ID (2003) Notch signaling in hematopoiesis., Sem Cell and Dev Biology, 14, 143-150
  • Meshinchi S, Stirewalt DL, Alonzo T, Sweetser DA, Woods WG, Bernstein ID, Arceci RO, Radich JP (2003) Activating mutations of RTK/ras signal transduction pathway in pediatric acute myeloid leukemia., Blood, 102 (4), 1474-9
  • Gopal AK, Gooley TA, Maloney DG, Petersdorf SH, Eary JF, Rajendran JG, Bush SA, Durack LD, Golden J, Martin PJ, Matthews DC, Appelbaum FR, Bernstein ID, Press OW (2003) High-Dose Radioimmunotherapy versus Conventional High-Dose Therapy and Autologous Hematopoietic Stem Cell Transplantation for Relapsed Follicular non-Hodgkins Lymphoma: A Multivariable Cohort Analysis., Blood, 102 (7), 2351-2356
  • Walter RB, Raden BW, Hong TC, Flowers DA, Bernstein ID, Linenberger ML (2003) Multidrug resistance protein (MRP) attenuates gemtuzumab ozogamicin-induced cytotoxicity in acute myeloid leukemia cells., Blood, 102, 1466-1473
  • Beeson C, Butrynski JE, Hart MJ, Nourigat C, Matthews DC, Press O, Senter PD, Bernstein ID (2003) Conditionally cleavable radioimmunoconjugates: a novel approach for the release of radioisotopes from radioimmunoconjugates., Bioconjugate Chem, 14 (5), 927-933
  • Johnston DL, Meshinchi S, Opheim KE, Pallavicini MG, Feusner J, Woods WG, Lange BJ, Radich JP, Bernstein ID (2003) Progenitor cell involvement is predictive of response to induction chemotherapy in paediatric acute myeloid leukaemia., Br J Haematol, 123 (3), 431-435
  • Hamann PR, Hinman LM, Beyer CF, Lindh D, Upeslacis J, Flowers DA, Bernstein I (2002) An anti-CD33 antibody-calicheamicin conjugate for treatment of acute myeloid leukemia. Choice of linker., Bioconjug Chem, 13, 40-46
  • Hamann PR, Hinman LM, Hollnader I, Beyer CF, Lindh D, Holcomb R, Hallett W, Tsou H-R, Upeslacis J, Shochat D, Mountain A, Flowers DA, Bernstein I (2002) Gemtuzumab ozogamicin, a potent and selective anti-CD33 antibody-calicheamicin conjugate for treatment of acute myeloid leukemia., Bioconjug Chem, 13, 47-58
  • Gopal AK, Rajendran JG, Petersdorf SH, Maloney DG, Eary JF, Wood BL, Gooley TA, Bush SA, Durack LD, Martin PJ, Matthews DC, Appelbaum FR, Bernstein ID, Press OW (2002) High-dose chemo-radioimmunotherapy with autologous stem cell support for relapsed mantle cell lymphoma., Blood, 99, 3158-3162
  • Pagel JM, Matthews DC, Appelbaum FR, Bernstein ID, Press OW (2002) The use of radioimmunoconjugates in stem cell transplantation (Mini-review)., Bone Marrow Transplantation, 29, 807-816
  • Bernstein ID (2002) CD33 as a target for selective ablation of acute myeloid leukemia., Clinical Lymphoma, 2, S9-S11
  • Ohishi K, Varnum-Finney B, Bernstein ID (2002) The notch pathway: modulation of cell fate decisions in hematopoiesis., International Journal of Hematology, 75, 449-566
  • Ohishi K, Varnum-Finney B, Bernstein ID (2002) Delta-1 enhances marrow and thymic repopulating ability of human CD34+CD38- cord blood cells., J Clin Invest, 110, 1165-1174
  • Larson RA, Boogaerts M, Estey E, Karanes C, Stadtmauer EA, Sievers EL, Mineur P, Bennett JM, Berger MS, Eten CB, Munteanu M, Loken M, van Dongen JJM, Bernstein ID, Appelbaum FR (2002) Antibody-targeted chemotherapy of older patients with acute myeloid leukemia in first relapse using Mylotarg (gemtuzumab ozogamicin)., Leukemia, 16, 1627-1636
  • Van der Velden VHJ, te Marvelde JG, Hoogeveen PG, Bernstein ID, Houtsmuller AB, Berger MS, van Dongen JJM (2001) Targeting of the CD33-calicheamicin immunoconjugate mylotarg (CMA-676) in acute myeloid leukemia: In vivo and in vitro saturation and internalization by leukemic and normal myeloid cells., Blood, 97, 3197-3204
  • Sievers EL, Larson RA, Stadtmauer EA, Estey E, Lowenberg B, Dombret H, Karanes C, Theobald M, Bennett JM, Sherman ML, Berger MS, Eten CB, Loken MR, van Dongen JJM, Bernstein ID, Appelbaum FR (2001) Efficacy and safety of Mylotarg (Gemtuzumab Ozogamicin) in patients with CD33-Positive Acute myeloid leukemia in first relapse., J Clin Oncol, 19, 3244-3254
  • Meshinchi S, Woods WG, Stirewalt DL, Sweetser DA, Buckley JD, Tjoa TK, Bernstein ID, Radich JP (2001) Prevalence and prognostic significance of FLT3 internal tandem duplication in pediatric acute myeloid leukemia., Blood, 97, 89-94
  • Sweetser DA, Chen C-S, Blomberg AA, Flowers DA, Galipeau PC, Barett MT, Heerema NA, Buckley J, Woods WG, Bernstein ID, Reid BJ (2001) Loss of heterozygosity in childhood de novo acute myelogenous leukemia., Blood, 98, 1188-1194
  • Linenberger ML, Hong T, Flowers D, Sievers EL, Gooley TA, Bennett JM, Berger MS, Leopold LH, Appelbaum FR, Bernstein ID (2001) Multidrug resistance phenotype and clinical responses to Mylotarg (Gemtuzumab Ozogamicin)., Blood, 98, 988-994
  • Ohishi K, Varnum-Finney B, Serda RE, Anasetti C, Bernstein ID (2001) The Notch ligand, delta-1, inhibits the differentiation of monocytes into macrophages but permits their differentiation into dendritic cells., Blood, 98, 1402-1407
  • Ruffner KL, Martin PJ, Hussell S, Nourigat C, Fisher DR, Bernstein ID, Matthews DC (2001) Immunosuppressive Effects of 131I-anti-CD45 Antibody in Unsensitized and Donor-Antigen Presensitized H2-Matched, Minor Antigen Mismatched Murine Transplant Models., Cancer Research, 61, 5126-5131
  • Varnum-Finney B, Xu L, Brashem-Stein C, Nourigat C, Flowers D, Bakkour S, Pear WS, Bernstein ID, Pluripotent, cytokine-dependent, hematopoietic stem cells are immortalized by constitutive Notch1 signaling, Nature Medicine, 6(11), 1278-81, November 2000 Abstract
  • Ohishi K, Varnum-Finney B, Flowers D, Anasetti C, Myerson D, Bernstein ID, Monocytes express high amounts of Notch and undergo cytokine specific apoptosis following interaction with the Notch ligand, Delta-1, Blood, 95(9), 2847-54, 2000 Abstract
  • Purton LE, Bernstein ID, Collins SJ, All-trans retinoic acid enhances the long-term repopulating activity of cultured hematopoietic stem cells., Blood, 95(2), 470-7, 15 2000 Abstract
  • Varnum-Finney B, Wu L, Yu M, Brashem-Stein C, Staats S, Flowers D, Griffin JD, Bernstein ID (2000) Immobilization of Notch ligand Delta-1 is required for induction of Notch signaling., J Cell Sci, 113, 4313-4318
  • Press OW, Eary JF, Gooley T, Gopal AK, Liu S, Rajendran JG, Maloney DG, Petersdorf S, Bush SA, Durack LD, Martin PJ, Fisher DR, Wood B, Borrow JW, Porter B, Smith JP, Matthews DC, Appelbaum FR, Bernstein ID (2000) A phaase I/II trial of iodine-131-tositumomab (anti-CD20), etoposide, cyclophosphamide, and autologous stem cell transplantation for relapsed B-cell lymphoma., Blood, 96, 2934-2942
  • Matthews DC, Appelbaum FR, Eary JF, Fisher DR, Durack LD, Hui TE, Martin PJ, Mitchell D, Press OW, Storb R, Bernstein ID, Phase I study of \(131\)I-anti-CD45 antibody plus cyclophosphamide and total body irradiation for advanced acute leukemia and myelodysplastic syndrome., Blood, 94(4), 1237-47, 15 Aug 1999 Abstract
  • Sievers EL, Appelbaum FR, Spielberger RT, Forman SJ, Flowers D, Smith FO, Shannon-Dorcy K, Berger MS, Bernstein ID, Selective ablation of acute myeloid leukemia using antibody-targeted chemotherapy: a phase I study of an anti-CD33 calicheamicin immunoconjugate., Blood, 93(11), 3678-84, 1 Jun 1999 Abstract
  • Matthews DC, Martin PJ, Nourigat C, Appelbaum FR, Fisher DR, Bernstein ID, Marrow ablative and immunosuppressive effects of 131I-anti-CD45 antibody in congenic and H2-mismatched murine transplant models., Blood, 93(2), 737-45, 15 Jan 1999 Abstract
  • Varnum-Finney B, Purton LE, Yu M, Brashem-Stein C, Flowers D, Staats S, Moore KA, Le Roux I, Mann R, Gray G, Artavanis-Tsakonas S, Bernstein ID, The Notch ligand, Jagged-1, influences the development of primitive hematopoietic precursor cells., Blood, 91(11), 4084-91, 1 1998 Abstract
  • Eary JF, Krohn KA, Press OW, Durack L, Bernstein ID, Importance of pre-treatment radiation absorbed dose estimation for radioimmunotherapy of non-Hodgkin''s lymphoma., Nuclear Medicine and Biology, 24(7), 635-8, October 1997 Abstract
  • Milner L A, Bigas A, Kopan R, Brashem-Stein C, Bernstein I D, Martin D I, Inhibition of granulocytic differentiation by mNotch1., Proceedings of the National Academy of Sciences (USA), 93(23), 13014-9, 12 Nov 1996 Abstract
  • Brashem-Stein C, Flowers D A, Bernstein I D, Regulation of colony forming cell generation by flt-3 ligand., British Journal of Haematology, 94(1), 17-22, July 1996 Abstract
  • Press O W, Shan D, Howell-Clark J, Eary J, Appelbaum F R, Matthews D, King D J, Haines A M, Hamann P, Hinman L, Shochat D, Bernstein I D, Comparative metabolism and retention of iodine-125, yttrium-90, and indium-111 radioimmunoconjugates by cancer cells., Cancer Research, 56(9), 2123-9, 1 May 1996 Abstract
  • McKenna H J, Smith F O, Brasel K, Hirschstein D, Bernstein I D, Williams D E, Lyman S D, Effects of flt3 ligand on acute myeloid and lymphocytic leukemic blast cells from children., Experimental Hematology, 24(2), 378-85, February 1996 Abstract
  • Smith FO, Rauch C, Williams DE, March CJ, Arthur D, Hilden J, Lampkin BC, Buckley JD, Buckley CV, Woods WG, Dinndorf PA, Sorensen P, Kersey J, Hammond D, Bernstein ID, The human homologue of rat NG2, a chondroitin sulfate proteoglycan, is not expressed on the cell surface of normal hematopoietic cells but is expressed by acute myeloid leukemia blasts from poor-progn, Blood, 87(3), 1123-33, 1 1996 Abstract
  • Behm FG, Smith FO, Raimondi SC, Pui CH, Bernstein ID, Human homologue of the rat chondroitin sulfate proteoglycan, NG2, detected by monoclonal antibody 7.1, identifies childhood acute lymphoblastic leukemias with t\(4;11\)\(q21;q23\) or t\(11;19\)\(q23;p, Blood, 87(3), 1134-9, 1 1996 Abstract
  • Sievers E L, Smith F O, Woods W G, Lee J W, Bleyer W A, Willman C L, Bernstein I D, Cell surface expression of the multidrug resistance P-glycoprotein (P-170) as detected by monoclonal antibody MRK-16 in pediatric acute myeloid leukemia fails to define a poor prognostic group: a repo, Leukemia, 9(12), 2042-8, December 1995 Abstract
  • Press O W, Eary J F, Appelbaum F R, Bernstein I D, Myeloablative radiolabeled antibody therapy with autologous bone marrow transplantation for relapsed B cell lymphomas., Cancer Treatment and Research, 76, 281-97, 1995 Abstract
  • Eary J F, Pollard K R, Durack L D, Bice A N, Lewellen T K, Matthews D, Press O W, Nelp W B, Appelbaum F R, Bernstein I, Post therapy imaging in high dose I-131 radioimmunotherapy patients., Medical Physics, 21(7), 1157-62, July 1994 Abstract
  • Nesbit M E Jr, Buckley J D, Feig S A, Anderson J R, Lampkin B, Bernstein I D, Kim T H, Piomelli S, Kersey J H, Coccia P F, et al, Chemotherapy for induction of remission of childhood acute myeloid leukemia followed by marrow transplantation or multiagent chemotherapy: a report from the Childrens Cancer Group [see comments], Journal of Clinical Oncology, 12(1), 127-35, January 1994 Abstract
  • Sorensen P H, Chen C S, Smith F O, Arthur D C, Domer P H, Bernstein I D, Korsmeyer S J, Hammond G D, Kersey J H, Molecular rearrangements of the MLL gene are present in most cases of infant acute myeloid leukemia and are strongly correlated with monocytic or myelomonocytic phenotypes., Journal of Clinical Investigation, 93(1), 429-37, January 1994 Abstract
  • Brashem-Stein C, Flowers D A, Smith F O, Staats S J, Andrews R G, Bernstein I D, Ontogeny of hematopoietic stem cell development: reciprocal expression of CD33 and a novel molecule by maturing myeloid and erythroid progenitors., Blood, 82(3), 792-9, 1 Aug 1993 Abstract
  • Nonoyama S, Smith F O, Bernstein I D, Ochs H D, Strain-dependent leakiness of mice with severe combined immune deficiency., Journal of Immunology, 150(9), 3817-24, 1 May 1993 Abstract
  • Press O W, Eary J, Badger C C, Appelbaum F R, Wiseman G, Matthews D, Martin P J, Bernstein I D, High-dose radioimmunotherapy of lymphomas., Cancer Treatment and Research, 68, 13-22, 1993 Abstract
  • Andrews R G, Bensinger W I, Knitter G H, Bartelmez S H, Longin K, Bernstein I D, Appelbaum F R, Zsebo K M, The ligand for c-kit, stem cell factor, stimulates the circulation of cells that engraft lethally irradiated baboons., Blood, 80(11), 2715-20, 1 Dec 1992 Abstract
  • Matthews D C, Smith F O, Bernstein I D, Monoclonal antibodies in the study and therapy of hematopoietic cancers., Current Opinion In Immunology, 4(5), 641-6, October 1992 Abstract
  • Andrews R G, Bryant E M, Bartelmez S H, Muirhead D Y, Knitter G H, Bensinger W, Strong D M, Bernstein I D, CD34+ marrow cells, devoid of T and B lymphocytes, reconstitute stable lymphopoiesis and myelopoiesis in lethally irradiated allogeneic baboons., Blood, 80(7), 1693-701, 1 Oct 1992 Abstract
  • Grossbard M L, Press O W, Appelbaum F R, Bernstein I D, Nadler L M, Monoclonal antibody-based therapies of leukemia and lymphoma., Blood, 80(4), 863-78, 15 Aug 1992 Abstract
  • Andrews R G, Bartelmez S H, Knitter G H, Myerson D, Bernstein I D, Appelbaum F R, Zsebo K M, A c-kit ligand, recombinant human stem cell factor, mediates reversible expansion of multiple CD34+ colony-forming cell types in blood and marrow of baboons., Blood, 80(4), 920-7, 15 Aug 1992 Abstract
  • Broudy V C, Smith F O, Lin N, Zsebo K M, Egrie J, Bernstein I D, Blasts from patients with acute myelogenous leukemia express functional receptors for stem cell factor., Blood, 80(1), 60-7, 1 Jul 1992 Abstract
  • Smith F O, Lampkin B C, Versteeg C, Flowers D A, Dinndorf P A, Buckley J D, Woods W G, Hammond G D, Bernstein I D, Expression of lymphoid-associated cell surface antigens by childhood acute myeloid leukemia cells lacks prognostic significance., Blood, 79(9), 2415-22, 1 May 1992 Abstract
  • Bernstein I D, Singer J W, Smith F O, Andrews R G, Flowers D A, Petersens J, Steinmann L, Najfeld V, Savage D, Fruchtman S, et al, Differences in the frequency of normal and clonal precursors of colony-forming cells in chronic myelogenous leukemia and acute myelogenous leukemia., Blood, 79(7), 1811-6, 1 Apr 1992 Abstract
  • Matthews D C, Badger C C, Fisher D R, Hui T E, Nourigat C, Appelbaum F R, Martin P J, Bernstein I D, Selective radiation of hematolymphoid tissue delivered by anti-CD45 antibody., Cancer Research, 52(5), 1228-34, 1 Mar 1992 Abstract
  • Schultz K R, Badger C C, Dombi G W, Greenberg P D, Bernstein I D, Effect of interleukin-2 on biodistribution of monoclonal antibody in tumor and normal tissues in mice bearing SL-2 thymoma., Journal of The National Cancer Institute, 84(2), 109-13, 15 Jan 1992 Abstract
  • Broudy V C, Lin N, Zsebo K M, Birkett N C, Smith K A, Bernstein I D, Papayannopoulou T, Isolation and characterization of a monoclonal antibody that recognizes the human c-kit receptor., Blood, 79(2), 338-46, 15 Jan 1992 Abstract
  • Appelbaum F R, Badger C C, Bernstein I D, Buckner C D, Deeg H J, Eary J F, Matthews D C, Press O W, Storb R, Thomas E D, Is there a better way to deliver total body irradiation?, Bone Marrow Transplantation, 10 Suppl 1, 77-81, 1992 Abstract
  • van der Jagt R H, Badger C C, Appelbaum F R, Press O W, Matthews D C, Eary J F, Krohn K A, Bernstein I D, Localization of radiolabeled antimyeloid antibodies in a human acute leukemia xenograft tumor model., Cancer Research, 52(1), 89-94, 1 Jan 1992 Abstract
  • Hui T E, Fisher D R, Press O W, Eary J F, Weinstein J N, Badger C C, Bernstein I D, Localized beta dosimetry of 131I-labeled antibodies in follicular lymphoma., Medical Physics, 19(1), 97-104, Winter 1992 Abstract
  • Dinndorf P A, Buckley J D, Nesbit M E, Lampkin B C, Piomelli S, Feig S A, Kersey J H, Hammond G D, Bernstein I D, Expression of myeloid differentiation antigens in acute nonlymphocytic leukemia: increased concentration of CD33 antigen predicts poor outcome--a report from the Childrens Cancer Study Group., Medical and Pediatric Oncology, 20(3), 192-200, 1992 Abstract
  • Badger C C, Rasey J, Nourigat C, Fisher D R, Hui T E, Wu Z M, Bernstein I D, WR2721 protection of bone marrow in 131I-labeled antibody therapy., Radiation Research, 128(3), 320-4, December 1991 Abstract
  • Bartelmez S H, Andrews R G, Bernstein I D, Uncovering the heterogeneity of hematopoietic repopulating cells [editorial], Experimental Hematology, 19(9), 861-2, October 1991 Abstract
  • Neiman P E, Torok-Storb B, Miller D, Bernstein I, Stem cell mysteries. Workshop on Stem Cell Biology sponsored by the Programs in Molecular Medicine of the Fred Hutchinson Cancer Research Center and the University of Washington, Seattle, WA, USA, Apr, New Biologist, 3(8), 741-4, August 1991 Abstract
  • Bernstein I D, Leary A G, Andrews R G, Ogawa M, Blast colony-forming cells and precursors of colony-forming cells detectable in long-term marrow culture express the same phenotype (CD33- CD34+)., Experimental Hematology, 19(7), 680-2, August 1991 Abstract
  • Bernstein I D, Andrews R G, Zsebo K M, Recombinant human stem cell factor enhances the formation of colonies by CD34+ and CD34+lin- cells, and the generation of colony-forming cell progeny from CD34+lin- cells cultured with interleukin-3,, Blood, 77(11), 2316-21, 1 Jun 1991 Abstract
  • Litzow M R, Brashem-Stein C, Andrews R G, Bernstein I D, Proliferative responses to interleukin-3 and granulocyte colony-stimulating factor distinguish a minor subpopulation of CD34-positive marrow progenitors that do not express CD33 and a novel antigen, 7, Blood, 77(11), 2354-9, 1 Jun 1991 Abstract
  • Berenson R J, Bensinger W I, Hill R S, Andrews R G, Garcia-Lopez J, Kalamasz D F, Still B J, Spitzer G, Buckner C D, Bernstein I D, et al, Engraftment after infusion of CD34+ marrow cells in patients with breast cancer or neuroblastoma., Blood, 77(8), 1717-22, 15 Apr 1991 Abstract
  • Sandmaier B M, Schuening F G, Bianco J A, Rosenman S J, Bernstein I, Goehle S, Storb R, Appelbaum F R, Biochemical characterization of a unique canine myeloid antigen., Leukemia, 5(2), 125-30, February 1991 Abstract
  • Schultz K R, Klarnet J P, Peace D J, Cheever M A, Badger C C, Bernstein I D, Greenberg P D, Monoclonal antibody therapy of murine lymphoma: enhanced efficacy by concurrent administration of interleukin 2 or lymphokine-activated killer cells., Cancer Research, 50(17), 5421-5, 1 Sep 1990 Abstract
  • Bianco J A, Brown P A, Durack L, Badger C, Bernstein I, Eary J, Durham J, Fisher D, Sandmaier B, Schuening F, et al, Effects of propylthiouracil on the biodistribution of an iodine-131-labeled anti-myeloid antibody in normal dogs: dosimetry and clinical implications., Journal of Nuclear Medicine, 31(8), 1384-9, August 1990 Abstract
  • Andrews R G, Singer J W, Bernstein I D, Human hematopoietic precursors in long-term culture: single CD34+ cells that lack detectable T cell, B cell, and myeloid cell antigens produce multiple colony-forming cells when cultured with marrow s, Journal of Experimental Medicine, 172(1), 355-8, 1 Jul 1990 Abstract
  • Bernstein I D, Eary J F, Badger C C, Press O W, Appelbaum F R, Martin P J, Krohn K A, Nelp W B, Porter B, Fisher D, et al, High dose radiolabeled antibody therapy of lymphoma., Cancer Research, 50(3 Suppl), 1017s-1021s, 1 Feb 1990 Abstract
  • Ali S A, Warren S D, Richter K Y, Badger C C, Eary J F, Press O W, Krohn K A, Bernstein I D, Nelp W B, Improving the tumor retention of radioiodinated antibody: aryl carbohydrate adducts., Cancer Research, 50(3 Suppl), 783s-788s, 1 Feb 1990 Abstract
  • Nourigat C, Badger C C, Bernstein I D, Treatment of lymphoma with radiolabeled antibody: elimination of tumor cells lacking target antigen., Journal of The National Cancer Institute, 82(1), 47-50, 3 Jan 1990 Abstract
  • Bensinger W I, Berenson R J, Andrews R G, Kalamasz D F, Hill R S, Bernstein I D, Lopez J G, Buckner C D, Thomas E D, Positive selection of hematopoietic progenitors from marrow and peripheral blood for transplantation., Journal of Clinical Apheresis, 5(2), 74-6, 1990 Abstract
  • Badger C C, Wilbur D S, Hadley S W, Fritzberg A R, Bernstein I D, Biodistribution of p-iodobenzoyl (PIP) labeled antibodies in a murine lymphoma model., International Journal of Radiation Applications and instrumentation. Part B, Nuclear Medicine and Biology, 17(4), 381-7, 1990 Abstract
  • Berenson R J, Bensinger W I, Hill R, Andrews R G, Garcia-Lopez J, Kalamasz D F, Still B J, Buckner C D, Bernstein I D, Thomas E D, Stem cell selection--clinical experience., Progress In Clinical and Biological Research, 333, 403-10; discussion 4, 1990 Abstract
  • Badger C C, Bernstein I D, Treatment of murine lymphoma with anti-Thy-1.1 antibodies., Immunology Series, 45, 515-29, 1989 Abstract

Profile Details

Last Updated: 8/1/2007

COS Expertise ID #307311
Reference this profile directly: http://myprofile.cos.com/bernstei11